Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea

Aliment Pharmacol Ther. 2006 Aug 15;24(4):613-9. doi: 10.1111/j.1365-2036.2006.03015.x.

Abstract

Background: Inhibition of gastric acid removes a defence against ingested bacteria and spores, increasing the risk of some forms of gastroenteritis. Previous studies investigating a possible link between acid suppression therapy and Clostridium difficile-associated diarrhoea have reported conflicting results.

Aim: To investigate whether acid suppression therapy is associated with an increased risk of C. difficile-associated diarrhoea. Prospective case-control study of 155 consecutive in-patients with C. difficile-associated diarrhoea.

Results: Antibiotics had been received by 143 (92%) of the C. difficile-associated diarrhoea group and 76 (50%) of the controls during the preceding 3 months. Among those receiving antibiotics, 59 (41%) of the C. difficile-associated diarrhoea group had also received acid suppression, compared with 21 (28%) of controls (OR 1.84, CI 1.01, 3.36, chi(2) = 4.0, P = 0.046). Among the entire C. difficile-associated diarrhoea group 64 (41%) had received acid suppression compared with 40 (26%) of controls (OR 1.99, CI 1.19, 3.31, chi(2) = 7.9, P = 0.005). Logistic regression analyses found that C. difficile-associated diarrhoea was independently associated with: antibiotic use (OR 13.1, 95% CI: 6.6, 26.1); acid suppression therapy (OR 1.90, 95% CI: 1.10, 3.29); and female sex (OR 1.79, 95% CI: 1.06, 3.04).

Conclusions: The risk of C. difficile-associated diarrhoea in hospitalized patients receiving antibiotics may be compounded by exposure to proton pump inhibitor therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antacids / adverse effects*
  • Case-Control Studies
  • Clostridioides difficile
  • Diarrhea / chemically induced*
  • Enterocolitis, Pseudomembranous / chemically induced*
  • Female
  • Humans
  • Male
  • Prospective Studies
  • Proton Pump Inhibitors*
  • Proton Pumps / adverse effects*
  • Recurrence
  • Risk Factors

Substances

  • Antacids
  • Proton Pump Inhibitors
  • Proton Pumps